Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection Inhibition Using Spike Protein Heptad Repeat-derived Peptides

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2004 May 20

PMID 15150417

Citations 243

Authors

Berend Jan Bosch

Byron E E Martina

Ruurd van der Zee

Jean Lepault

Bert Jan Haijema

Cees Versluis

Albert J R Heck

Raoul De Groot

Albert D M E Osterhaus

Peter J M Rottier

Affiliations

Soon will be listed here.

Abstract

The coronavirus SARS-CoV is the primary cause of the life-threatening severe acute respiratory syndrome (SARS). With the aim of developing therapeutic agents, we have tested peptides derived from the membrane-proximal (HR2) and membrane-distal (HR1) heptad repeat region of the spike protein as inhibitors of SARS-CoV infection of Vero cells. It appeared that HR2 peptides, but not HR1 peptides, were inhibitory. Their efficacy was, however, significantly lower than that of corresponding HR2 peptides of the murine coronavirus mouse hepatitis virus (MHV) in inhibiting MHV infection. Biochemical and electron microscopical analyses showed that, when mixed, SARS-CoV HR1 and HR2 peptides assemble into a six-helix bundle consisting of HR1 as a central triple-stranded coiled coil in association with three HR2 alpha-helices oriented in an antiparallel manner. The stability of this complex, as measured by its resistance to heat dissociation, appeared to be much lower than that of the corresponding MHV complex, which may explain the different inhibitory potencies of the HR2 peptides. Analogous to other class I viral fusion proteins, the six-helix complex supposedly represents a postfusion conformation that is formed after insertion of the fusion peptide, proposed here for coronaviruses to be located immediately upstream of HR1, into the target membrane. The resulting close apposition of fusion peptide and spike transmembrane domain facilitates membrane fusion. The inhibitory potency of the SARS-CoV HR2-peptides provides an attractive basis for the development of a therapeutic drug for SARS.

Citing Articles

Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity.

Mougari S, Favede V, Predella C, Reynard O, Durand S, Mazelier M Commun Biol. 2025; 8(1):57.

PMID: 39814955 PMC: 11735783. DOI: 10.1038/s42003-025-07491-4.

Developing peptide-based fusion inhibitors as an antiviral strategy utilizing coronin 1 as a template.

Panda M, Qazi B, Vishwakarma V, Pattnaik G, Haldar S, Chakraborty H RSC Med Chem. 2024; .

PMID: 39399312 PMC: 11467784. DOI: 10.1039/d4md00523f.

In silico screening and evaluation of antiviral peptides as inhibitors against ORF9b protein of SARS-CoV-2.

Sharma G, Paul P, Dviwedi A, Kaur P, Kumar P, Kumar Gupta V 3 Biotech. 2024; 14(9):192.

PMID: 39118822 PMC: 11303353. DOI: 10.1007/s13205-024-04032-4.

En route to Peptide Therapeutics for COVID 19: Harnessing Potential Antigenic Mimicry Between Viral and Human Proteins.

Madhavan M, Mustafa S Trans Indian Natl Acad Eng. 2024; 5(2):411-415.

PMID: 38624407 PMC: 7306100. DOI: 10.1007/s41403-020-00132-8.

Helix-based screening with structure prediction using artificial intelligence has potential for the rapid development of peptide inhibitors targeting class I viral fusion.

Suzuki S, Kuroda M, Aoki K, Kawaji K, Hiramatsu Y, Sasano M RSC Chem Biol. 2024; 5(2):131-140.

PMID: 38333196 PMC: 10849125. DOI: 10.1039/d3cb00166k.

References

Schagger H, von Jagow G . Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987; 166(2):368-79. DOI: 10.1016/0003-2697(87)90587-2. View

de Groot R, Luytjes W, Horzinek M, van der Zeijst B, Spaan W, Lenstra J . Evidence for a coiled-coil structure in the spike proteins of coronaviruses. J Mol Biol. 1987; 196(4):963-6. PMC: 7131189. DOI: 10.1016/0022-2836(87)90422-0. View

Yoo D, Parker M, Babiuk L . The S2 subunit of the spike glycoprotein of bovine coronavirus mediates membrane fusion in insect cells. Virology. 1991; 180(1):395-9. PMC: 7131255. DOI: 10.1016/0042-6822(91)90045-d. View

Chambers P, Pringle C, Easton A . Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J Gen Virol. 1990; 71 ( Pt 12):3075-80. DOI: 10.1099/0022-1317-71-12-3075. View

Wild C, Oas T, McDanal C, Bolognesi D, Matthews T . A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A. 1992; 89(21):10537-41. PMC: 50374. DOI: 10.1073/pnas.89.21.10537. View

Wild C, Shugars D, Greenwell T, McDanal C, Matthews T . Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A. 1994; 91(21):9770-4. PMC: 44898. DOI: 10.1073/pnas.91.21.9770. View

Taguchi F . The S2 subunit of the murine coronavirus spike protein is not involved in receptor binding. J Virol. 1995; 69(11):7260-3. PMC: 189649. DOI: 10.1128/JVI.69.11.7260-7263.1995. View

Blacklow S, Lu M, Kim P . A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry. 1995; 34(46):14955-62. DOI: 10.1021/bi00046a001. View

Rapaport D, Ovadia M, Shai Y . A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. EMBO J. 1995; 14(22):5524-31. PMC: 394666. DOI: 10.1002/j.1460-2075.1995.tb00239.x. View

10.

Lu M, Blacklow S, Kim P . A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol. 1995; 2(12):1075-82. DOI: 10.1038/nsb1295-1075. View

11.

Lambert D, Barney S, Lambert A, Guthrie K, Medinas R, Davis D . Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A. 1996; 93(5):2186-91. PMC: 39932. DOI: 10.1073/pnas.93.5.2186. View

12.

Fass D, Kim P . Dissection of a retrovirus envelope protein reveals structural similarity to influenza hemagglutinin. Curr Biol. 1995; 5(12):1377-83. DOI: 10.1016/s0960-9822(95)00275-2. View

13.

Chan D, Fass D, Berger J, Kim P . Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997; 89(2):263-73. DOI: 10.1016/s0092-8674(00)80205-6. View

14.

Weissenhorn W, Dessen A, Harrison S, Skehel J, Wiley D . Atomic structure of the ectodomain from HIV-1 gp41. Nature. 1997; 387(6631):426-30. DOI: 10.1038/387426a0. View

15.

Luo Z, Weiss S . Roles in cell-to-cell fusion of two conserved hydrophobic regions in the murine coronavirus spike protein. Virology. 1998; 244(2):483-94. PMC: 7130564. DOI: 10.1006/viro.1998.9121. View

16.

Joshi S, Dutch R, Lamb R . A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41. Virology. 1998; 248(1):20-34. DOI: 10.1006/viro.1998.9242. View

17.

Baker K, Dutch R, Lamb R, Jardetzky T . Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell. 1999; 3(3):309-19. DOI: 10.1016/s1097-2765(00)80458-x. View

18.

Kuo L, Godeke G, Raamsman M, Masters P, Rottier P . Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J Virol. 2000; 74(3):1393-406. PMC: 111474. DOI: 10.1128/jvi.74.3.1393-1406.2000. View

19.

van Berkel W, van den Heuvel R, Versluis C, Heck A . Detection of intact megaDalton protein assemblies of vanillyl-alcohol oxidase by mass spectrometry. Protein Sci. 2000; 9(3):435-9. PMC: 2144579. DOI: 10.1110/ps.9.3.435. View

20.

Zhao X, Singh M, Malashkevich V, Kim P . Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci U S A. 2000; 97(26):14172-7. PMC: 18890. DOI: 10.1073/pnas.260499197. View